Robert Lechleider

CMO Robert Lechleider sells 55,000 shares (77.7% of holdings) at $21.95–$23.44 via scheduled 10b5-1 plan

Robert Lechleider, Chief Medical Officer of Immunome Inc., executed 3 separate sales totaling 55,000 shares for $1,244,330.62 on 2026-07-02 under a pre-arranged 10b5-1 trading plan adopted on 2026-03-26. The sales reduced his non-derivative holdings from 70,805 shares to 15,805 shares, representing a 77.7% reduction, though he retains 290,000 employee stock options. The blended transaction price of $22.62 falls below the current market price of $24.39 and within the stock's 52-week range of $7.96–$27.65. The company remains unprofitable with a net income of -$53,839,000 and negative annual revenue growth of -23.2%, establishing a financially distressed backdrop. Since the transaction is governed by a scheduled 10b5-1 plan rather than discretionary timing, the trade reflects contract-based execution rather than reactive market positioning. Investors should note the substantial reduction in direct share ownership by the CMO while factoring in the non-discretionary nature of the sale.

CMO Robert Lechleider sold 55,000 shares (77.7% of holdings) for $1.1M via scheduled 10b5-1 plan at IMNM

Robert Lechleider, Chief Medical Officer at Immunome Inc., executed 2 separate sales totaling 55,000 shares for $1,091,662.00 on 2026-06-25 through a pre-arranged 10b5-1 trading plan adopted 2026-03-26. The transactions reduced his direct shareholdings from 70,805 shares to 15,805 shares, though he retains 345,000 shares through employee stock options. The company is unprofitable (net income of $-53,839,000.00 most recently) with negative annual revenue growth of -23.2%. At the transaction prices (blended average $19.85), Lechleider sold near the current price of $21.04 and within the 52-week range ($7.96–$27.65). As a scheduled 10b5-1 execution, this sale reflects pre-commitment under Rule 10b5-1 mechanics rather than a discretionary market-timing decision.

CMO Robert Lechleider buys 15,805 shares at $9.48; 2 other insiders also bought in past 14 days

Robert Lechleider, Chief Medical Officer, purchased 15,805 shares at $9.48 on 2024-11-21, establishing his first position at this company. This transaction is part of a cluster pattern: 2 other insiders also bought within the past 14 days. The context is material: Immunome reported a net income of $-47,100,000.00 over its most recent full fiscal year, with the stock currently 59.2% below its 52-week high of $27.34. The cluster buying by multiple insiders during a period of unprofitability and significant price decline merits investor scrutiny into the underlying rationale and any non-public information that might have prompted coordinated accumulation at this level.